MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

Rhea-AI Summary

MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies, announced the release of its first quarter 2023 financial results on May 11, 2023. The company will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide corporate updates. The conference call will be accessible via phone and online, with dedicated dial-in numbers for participants in the USA and Canada. MiNK is advancing its pipeline of native and engineered iNKT programs aimed at treating cancer and other immune-mediated diseases, emphasizing scalable manufacturing for off-the-shelf delivery.

Positive

• Scheduled release of Q1 2023 financial results indicates transparency and ongoing communication with stakeholders.
• Company's focus on developing off-the-shelf iNKT therapies may position it advantageously in the biopharmaceutical market.

Negative

• None.

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

Conference Call

Dial in numbers: 646-307-1963 (USA-NY), 800-715-9871 (USA & Canada)

Conference ID: 8437743

Webcast

A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/4c4qmbci.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.

Contact

Alexa Buffa
781-674-4428
communications@minktherapeutics.com

Investor relations
Zack Armen
917-362-1370
investor@minktherapeutics.com

FAQ

When will MiNK Therapeutics release its Q1 2023 financial results?

MiNK Therapeutics will release its Q1 2023 financial results on May 11, 2023.

What time is the MiNK Therapeutics conference call to discuss financial results?

The conference call will take place at 8:30 a.m. ET on May 11, 2023.

How can I access the MiNK Therapeutics conference call?

The conference call can be accessed via phone at specified numbers or through a live webcast on the company's events page.

What is MiNK Therapeutics focused on developing?

MiNK Therapeutics is focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.